1062368-62-0,
LDN193189 Hydrochloride,
LDN-193189 hydrochloride,
LDN193189 HCl,
UNII-PLH51K438W,
LDN-193189 HCl,
PLH51K438W,
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride,
LDN 193189 hydrochloride,
LDN-193189 monohydrochloride,
4-{6-[4-(piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline hydrochloride,
LDN193189(Hydrochloride),
MLS006011214,
SCHEMBL2059683,
KS-00001CVJ,
FD7108,
MFCD17392570,
NSC747884,
AKOS026673959,
NSC-747884,
AC-28455,
AK198728,
Quinoline, 4-(6-(4-(1-piperazinyl)phenyl)pyrazolo(1,5-a)pyrimidin-3-yl)-, hydrochloride (1:1),
SMR004702976,
S7507,
Y6631,
LDN193189 hydrochloride, >=98% (HPLC),
W-5690,
4-(6-(4-(PIPERAZIN-1-YL)PHENYL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)QUINOLINE HCL,
4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline;hydrochloride,
4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline hydrochloride,
4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline hydrochloride,
LDN193189 (Hydrochloride),
C25H23ClN6,
A3545,
LDN193189 hydrochloride, 98%, a selective BMP type I receptor kinases inhibitor - 10MG 10mg,